Pro-Dex (PDEX) Q4 2026 earnings summary

Executive summary

• Fiscal 2026 saw strong growth, with net sales up 16% year-over-year to $77.5 million, driven by increased demand for next generation orthopedic handpieces and the acquisition of APM.

• Gross profit rose 25% to $24.3 million, and net income increased 52% to $13.7 million, reflecting improved margins and gains on marketable equity investments.

• The fourth quarter delivered a 17% sales increase and a 103% jump in gross profit compared to the same quarter last year, with gross margin expanding to 35%.

Financial highlights

• Q4 net sales reached $20.4 million, up $2.9 million year-over-year; gross profit doubled to $7.1 million.

• Full-year operating income rose 22% to $13.0 million; net income per diluted share was $4.12, up from $2.67.

• Gains on marketable equity investments contributed $5.7 million to net income in fiscal 2026.

• Cash and cash equivalents at year-end were $8.2 million, up from $419,000 the prior year.

Outlook and guidance

• Management expressed confidence in continued growth following the successful integration of APM and strong sales momentum.

• Forward-looking statements caution that actual results may differ due to various operational and business risks.